CAR-T in solid tumors: Obstacles and potential strategies
- 1State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai 201203, China
Abstract
Chimeric antigen receptor T (CAR-T) cell therapy has achieved remarkable success in treating hematologic malignancies, yet its efficacy in solid tumors remains constrained by multiple challenges. In this review, we summarize the main obstacles hindering CAR-T therapy in solid tumors, including suboptimal antigen targeting, poor trafficking and infiltration into tumor sites, and insufficient persistence of CAR-T cells. Furthermore, we discuss emerging strategies to overcome these hurdles, which can be categorized into two complementary aspects. The first focuses on optimizing intrinsic CAR-T properties for improved adaptation to the tumor microenvironment (TME), such as enriching less-differentiated T cell subsets, modifying CAR constructs, refining ex vivo culture conditions, and modulating specific genes or metabolic pathways through genetic or pharmacological interventions. The second approach aims to remodel the immunosuppressive TME by neutralizing inhibitory mediators, blocking immune checkpoints, and targeting immunosuppressive cell populations and stromal components. Importantly, we also summarized recent progress in in vivo CAR-T therapy. This review provides a comprehensive overview of the obstacles facing CAR-T in solid tumors, addressing both the underlying mechanisms and the translational potential of current and future strategies.
Related
- CAR-T cell therapy for solid tumors: antigen landscape, biological barriers, and engineering strategies for clinical translation
- Innovations and emerging trends in adoptive cell therapies for solid tumors: engineering strategies and clinical translation
- Editorial: Chemoresistance and immunotherapy in solid tumors
- Editorial: Autophagy in solid tumors and inflammation: mechanisms and therapies
- Development and Temporal Validation of a Three-Metabolite Cerebrospinal Fluid Model for the Diagnosis of Leptomeningeal Metastasis from Solid Tumors
BibTeX
@article{ding2026cart,
title = {{CAR-T in solid tumors: Obstacles and potential strategies}},
author = {Ziyi Ding and Yize Li and Min Huang},
journal = {Acta pharmaceutica Sinica. B},
year = {2026},
month = jul,
doi = {10.1016/j.apsb.2026.07.047},
url = {https://europepmc.org/article/PMC/PMC13729542},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - CAR-T in solid tumors: Obstacles and potential strategies
AU - Ziyi Ding
AU - Yize Li
AU - Min Huang
PY - 2026
DA - 2026/07/31
JO - Acta pharmaceutica Sinica. B
DO - 10.1016/j.apsb.2026.07.047
UR - https://europepmc.org/article/PMC/PMC13729542
AB - Chimeric antigen receptor T (CAR-T) cell therapy has achieved remarkable success in treating hematologic malignancies, yet its efficacy in solid tumors remains constrained by multiple challenges. In this review, we summarize the main obstacles hindering CAR-T therapy in solid tumors, including suboptimal antigen targeting, poor trafficking and infiltration into tumor sites, and insufficient persistence of CAR-T cells. Furthermore, we discuss emerging strategies to overcome these hurdles, which can be categorized into two complementary aspects. The first focuses on optimizing intrinsic CAR-T properties for improved adaptation to the tumor microenvironment (TME), such as enriching less-differentiated T cell subsets, modifying CAR constructs, refining ex vivo culture conditions, and modulating specific genes or metabolic pathways through genetic or pharmacological interventions. The second approach aims to remodel the immunosuppressive TME by neutralizing inhibitory mediators, blocking immune checkpoints, and targeting immunosuppressive cell populations and stromal components. Importantly, we also summarized recent progress in in vivo CAR-T therapy. This review provides a comprehensive overview of the obstacles facing CAR-T in solid tumors, addressing both the underlying mechanisms and the translational potential of current and future strategies.
SN - 2211-3835
SN - 2211-3843
ER -